

66793 U.S. PTO  
05/12/98

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975. PTO/SB/06 (12/87)

Approved for use through 09/30/00. OMB 0851-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <small>(Only for new nonprovisional applications under 37 CFR 1.63(b))</small>		<b>Attorney Docket No.</b> 279-20606	<b>Total Pages</b>
<b>First Named Inventor or Application Identifier</b>			
Masako KIMURA et al.			
<b>Express Mail Label No. not applicable</b>			

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>	<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231
--	---

1. ☒ **Fee Transmittal Form**  
(Submit an original, and a duplicate for fee processing)

2. ☒ **Specification** [Total Pages - 18]  
(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. ☐ **Drawing(s)** (35 USC 113) [Total sheets - 0]

4. ☒ **Oath or Declaration** [Total Pages - 3]

a. ☒ Newly executed (original or copy)

b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)  
**[Note Box 5 below]**

i. ☐ **DELETION OF INVENTOR(S)**  
 Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

5. ☐ **Incorporation By Reference**  
(usable if Box 4b is checked)  
 The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ **Microfiche Computer Program** (Appendix)

7. **Nucleotide and/or Amino Acid Sequence Submission**  
(if applicable, all necessary)

a. ☐ Computer Readable Copy

b. ☐ Paper Copy (identical to computer copy)

c. ☐ Statement verifying identity of above copies

<b>ACCOMPANYING APPLICATION PARTS</b>
<p>8. <input checked="" type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <span style="float: right;"><input type="checkbox"/> Power of Attorney</span>  <small>(when there is an assignee)</small></p> <p>10. <input type="checkbox"/> English Translation Document <small>(if applicable)</small></p> <p>11. <input type="checkbox"/> Information Disclosure <span style="float: right;"><input type="checkbox"/> Copies of IDS</span>  <small>Statement (IDS)/PTO-1449 Citations</small></p> <p>12. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)  <small>(Should be specifically itemized)</small></p> <p>14. <input type="checkbox"/> Small Entity Statement(s)  <span style="margin-left: 20px;"><input type="checkbox"/> Statement filed in prior application, Status still proper and desired</span></p> <p>15. <input checked="" type="checkbox"/> Certified Copy of Priority Document(s)  <small>(if foreign priority is claimed)</small></p> <p>16. <input type="checkbox"/> Other</p>

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:  
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. \_\_\_\_\_.

**18. CORRESPONDENCE ADDRESS**

WENDEROTH, LIND & PONACK, L.L.P.  
 2033 K Street, N.W., Suite 800  
 Washington, D.C. 20006

Phone: (202) 721-8200  
 Fax: (202) 721-8250

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Masako KIMURA et al. :  
Serial No. [NEW] : Attn: APPLICATION BRANCH  
Filed May 12, 1998 : Attorney Docket No.  
279-20606  
COMPOSITIONS CONTAINING :  
DIFLUPREDNATE :

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents  
Washington, DC 20231

COPY, FINANCE DEPT., USPTO  
CHARGE DEFICIENCIES  
TO DEPOSIT ACCT. # 23-0975

Sir:

Attached hereto is a check in the amount of \$830.00 to cover Patent Office fees relating to  
filing the following attached papers:

New application . . . . . \$790.00

Assignment for Recordal . . . . . \$ 40.00

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office  
of Finance.

*The Commissioner is authorized to charge any deficiency or to credit any overpayment  
associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of  
deficiencies in fees for multiple dependent claims in new applications.*

Respectfully submitted,

Masako KIMURA et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
for Matthew Jacob  
Registration No. 25,154  
Attorney for Applicants

MJ/WMC/adc  
WENDEROTH, LIND & PONACK, L.L.P.  
2033 K St., N.W., Suite 800  
Washington, D.C. 20006  
Telephone (202) 721-8200  
May 12, 1998

[Check No. 28399]

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Masako KIMURA et al. :  
Serial No. [NEW] : Attn: Application Branch  
Filed May 12, 1998 : Attorney Docket No.  
279-20606  
COMPOSITIONS CONTAINING :  
DIFLUPREDNATE :

PRELIMINARY AMENDMENT TO REDUCE PTO FILING FEES

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

In the interest of compact prosecution and to reduce PTO filing fees, please amend the present application as follows:

IN THE CLAIMS:

Claim 11, line 1, change "any one of claims 1 to 4" to --claim 1--.

Claim 12, line 1, change "any one of claims 1 to 4" to --claim 1--.

Please add the following new claims:

--13. The composition of claim 2, which is an oil-in-water type emulsion.

14. The composition of claim 3, which is an oil-in-water type emulsion.

15. The composition of claim 4, which is an oil-in-water type emulsion.

16. The composition of claim 2, which is in the form of an eye drop, a nasal drop or an ear drop.

17. The composition of claim 3, which is in the form of an eye drop, a nasal drop or an ear drop.

18. The composition of claim 4, which is in the form of an eye drop, a nasal drop or an ear drop.--

REMARKS


The above amendment is presented to eliminate multiple dependent claims, thereby reducing PTO filing fees.

Favorable action on the merits is now requested.

Respectfully submitted,

Masako KIMURA et al.

By

  
Warren M. Cheek, Jr.  
Registration No. 33,367  
for Matthew Jacob  
Registration No. 25,154  
Attorney for Applicants

MJ/WMC/adc  
Washington, D.C.  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
May 12, 1998

# **SPECIFICATION**

## **COMPOSITIONS CONTAINING DIFLUPREDNATE**

### **TECHNICAL FIELD OF THE INVENTION**

The present invention relates to a liquid composition containing difluprednate, oil, water and an emulsifier. More particularly, the present invention relates to a liquid composition containing difluprednate, which permits uniform drug distribution and superior transfer of difluprednate into a lesion, and which is associated with less uncomfortable feeling and foreign sensation.

### **BACKGROUND OF THE INVENTION**

Difluprednate (6  $\alpha$ , 9  $\alpha$  -difluoroprednisolone 17-butyrate 21-acetate) is an antiinflammatory steroid which is known to show superior antiinflammatory action by percutaneous administration (US Patent Nos. 3780177, 3784692). In addition, difluprednate is reported to show superior antiinflammatory action and antiallergic action by percutaneous administration and subcutaneous administration (Pharmacometrics, 29 (3), 343-353 (1985), Pharmacometrics, 29 (3), 355-362 (1985)). Therefore, difluprednate is mainly used as a therapeutic drug in the preparation form of ointment, cream and the like for skin disorders.

On the other hand, when difluprednate is administered locally to an eye, nose, ear or the like, a liquid dosage form, such as an eye drop, a nasal drop, an ear drop and the like, is desirable. However, inasmuch as difluprednate has extremely low solubility in water, it is difficult to prepare a stable eye drop, nasal drop, ear drop or the like, containing difluprednate in a concentration effective for treatment, and a dosage form of an aqueous suspension has been proposed for the administration to the local sites as mentioned above (US Patent No. 5556848).

When, for example, an aqueous suspension of difluprednate is used as an eye drop, however, common problems associated with aqueous ophthalmic suspensions, namely, difficulty in sustaining uniform drug distribution upon instillation, uncomfortable feeling caused by solid entering into the eye and inability to completely eliminate foreign sensation, have been pointed out. In addition, since difluprednate is an antiinflammatory steroid, it is on the one hand sufficiently effective for the treatment of inflammatory diseases, allergic diseases and the like, but on the other hand associated with side effects. Thus, there is a need for the development of a dosage form permitting quick

and uniform transfer of an effective amount of difluprednate and causing less side effects, in view of a case where a part (e.g., inner ocular area) distant from the instillation site (e.g., outer ocular area) has an inflammation.

### SUMMARY OF THE INVENTION

As mentioned above, since difluprednate has superior antiinflammatory action and antiallergic action, it is useful for the prophylaxis and treatment of various inflammatory diseases and allergic diseases. When it is applied for the treatment of diseases in the eye, nose, ear and the like, it needs to be formulated into an administration dosage form permitting instillation in the eye, nose, ear and the like. When difluprednate is used in the form of an aqueous suspension for the treatment of these local diseases, however, the above-mentioned problems in terms of transfer of the drug to the lesion, distribution of the drug and feeling in use, such as uncomfortable feeling and foreign sensation, remain to be solved.

It is therefore an object of the present invention to provide a composition containing difluprednate, which shows superior transfer of the drug to the lesion, uniform drug distribution upon administration, less uncomfortable feeling and foreign sensation upon administration, and less side effects.

According to the present invention, it has now been found that a dosage form of a liquid composition containing difluprednate, oil, water and an emulsifier results in quick transfer of a large amount of difluprednate, uniform drug distribution and extremely reduced levels of uncomfortable feeling and foreign sensation upon local administration to the eye, nose, ear and the like. Inasmuch as difluprednate can be transferred smoothly, administration of a small dose thereof is sufficient to bring about efficacy, whereby side effects can be suppressed.

That is, the present invention provides the following.

- (1) A difluprednate liquid composition comprising difluprednate, oil, water and an emulsifier.
- (2) The composition of (1) above, comprising 10-100,000 parts by weight of oil, 100-100,000 parts by weight of water and 10-100,000 parts by weight of the emulsifier, per part by weight of difluprednate.
- (3) The composition of (1) above, comprising 10-10,000 parts by weight of oil, 100-50,000 parts by weight of water and 10-10,000 parts by weight of the emulsifier, per part by weight of difluprednate.
- (4) The composition of (1) above, comprising 10-5,000 parts by weight of oil,

500-50,000 parts by weight of water and 10-5,000 parts by weight of the emulsifier, per part by weight of difluprednate.

(5) The composition of (1) above, wherein the oil comprises a fatty acid ester of glycerol.

(6) The composition of (5) above, wherein the fatty acid ester of glycerol is a member selected from the group consisting of castor oil, peanut oil, cotton seed oil, soybean oil, olive oil and a medium chain fatty acid triglyceride.

(7) The composition of (1) above, wherein the emulsifier comprises a surfactant.

(8) The composition of (7) above, wherein the surfactant is a nonionic surfactant.

(9) The composition of (8) above, wherein the nonionic surfactant is a member selected from the group consisting of polyoxyethylene hydrogenated castor oil and a polyoxyethylenesorbitan fatty acid ester.

(10) The composition of (9) above, wherein the polyoxyethylenesorbitan fatty acid ester is a member selected from the group consisting of polyoxyethylene-sorbitan monooleate, polyoxyethylenesorbitan monolaurate, polyoxyethylene-sorbitan monopalmitate and polyoxyethylenesorbitan monostearate.

(11) The composition of any one of (1) to (4) above, which is an oil-in-water type emulsion.

(12) The composition of any one of (1) to (4) above, which is in the form of an eye drop, a nasal drop or an ear drop.

#### DETAILED DESCRIPTION OF THE INVENTION

The composition of the present invention contains difluprednate, oil, water and an emulsifier. The oil usable in the present invention may be any as long as it is applicable to the eye, and is low toxic and less irritant to the eye. Preferably, an oil containing a fatty acid ester of glycerol, such as castor oil, peanut oil, cotton seed oil, soybean oil, olive oil, medium chain fatty acid triglycerides (e.g., Miglyol, trademark, manufactured by Mitsuba Boeki) and the like, is used. More preferably, castor oil, medium chain fatty acid triglycerides (e.g., Miglyol) and the like, in which difluprednate is highly soluble, can be used.

In the present invention, a surfactant, such as a nonionic surfactant having surface activating capability and the like, may be contained as an emulsifier. Examples of the nonionic surfactant include polyoxyethylene hydrogenated castor oils and polyoxyethylenesorbitan fatty acid esters, preferably polyoxyethylenesorbitan monooleates, polyoxyethylenesorbitan

monolaurates, polyoxyethylenesorbitan monopalmitates, polyoxyethylenesorbitan monostearates and the like.

While the ratio of each of the above-mentioned ingredients in the composition of the present invention is not particularly limited, it is preferable that oil be contained in a proportion of 10-100,000 parts by weight, water in a proportion of 100-100,000 parts by weight and emulsifier in a proportion of 10-100,000 parts by weight, all per part by weight of difluprednate; preferably in the proportions of oil 10-10,000 parts by weight, water 100-50,000 parts by weight and emulsifier 10-10,000 parts by weight, all per part by weight of difluprednate; and particularly preferably in the proportions of oil 10-5,000 parts by weight, water 500-50,000 parts by weight and emulsifier 10-5,000 parts by weight, all per part by weight of difluprednate.

It is particularly preferable that the weight ratio of water (which is a medium) to oil be 4:1-99:1.

The composition of the present invention may contain a water soluble polymer for enhanced stabilization of emulsion. Examples of the water soluble polymer include povidone (polyvinylpyrrolidone), polyvinyl alcohol, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and salt thereof, and the like.

The composition of the present invention may contain a buffer. Examples of the buffer include acetates such as sodium acetate and the like, phosphates such as sodium dihydrogenphosphate, disodium hydrogenphosphate, potassium dihydrogenphosphate, dipotassium hydrogenphosphate and the like,  $\epsilon$ -aminocaproic acid, amino acid salts such as sodium glutamate and the like, boric acid and salt thereof, citric acid and salt thereof, and the like.

The composition of the present invention may contain a preservative. Examples of the preservative include quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride and the like; cationic compounds such as chlorhexidine gluconate and the like; p-hydroxybenzoates such as methyl p-hydroxybenzoate, propyl p-hydroxybenzoate and the like; alcohol compounds such as chlorobutanol, benzyl alcohol and the like; sodium dehydroacetate; thimerosal; sorbic acid; and the like.

The composition of the present invention may contain an isotonizing agent. Examples of the isotonizing agent include sodium chloride, glycerol,



glucose, mannitol, sorbitol and the like.

The composition of the present invention may also contain various additives, such as a stabilizer, an antioxidant, a chelating agent, a pH adjusting agent, a thickener and the like. Examples of the antioxidant include ascorbic acid and salt thereof, tocopherol, sodium thiosulfate, sodium hydrogensulfite, pyruvic acid and salt thereof, and the like. The chelating agent is exemplified by sodium edetate, citric acid and salt thereof, and the like. Examples of the pH adjusting agent include hydrochloric acid, phosphoric acid, acetic acid, sulfuric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogencarbonate, aqueous ammonia and the like.

The composition of the present invention can be provided as an aqueous preparation of oil-in-water type (O/W type) emulsion, microemulsion and the like.

An oil drop of the composition of the present invention has a median size of preferably  $5-0.0001 \mu\text{m}$ , more preferably  $1-0.001 \mu\text{m}$ , and particularly preferably  $1-0.01 \mu\text{m}$ . The median size can be measured by an apparatus for particle size distribution.

The composition of the present invention preferably has a pH of 3-8. More preferable pH is 4-7, at which difluprednate is more stabilized.

The composition of the present invention is prepared by emulsifying oil, in which difluprednate has been dissolved, and water, using an emulsifier according to a known method. For example, an emulsifier and the above-mentioned additive, as necessary, are added to water, its pH is adjusted to 3-8 with a pH adjusting agent, and oil, in which difluprednate has been dissolved, is added to give an emulsion. For uniform emulsification, a known means, such as a homomixer, homogenizer, microfluidizer, high pressure homogenizer and the like, may be used.

The composition of the present invention is preferably used as a preparation for local administration to the eye, nose or ear, and more preferably used as an eye drop, nasal drop or ear drop.

The composition of the present invention has superior antiinflammatory action and antiallergic action. In addition, it shows superior transfer of difluprednate in a large amount, uniform drug distribution and extremely reduced levels of uncomfortable feeling and foreign sensation upon administration. In addition, administration of a small dose thereof is sufficient to produce efficacy, whereby side effects can be suppressed.

Therefore, it is useful for the prophylaxis and treatment of various inflammatory diseases and allergic diseases, such as allergic conjunctivitis, vernal conjunctivitis, blepharitis marginalis, catarrhal conjunctivitis, uveitis and the like, and it can be beneficially used for local administration to the eye, nose, ear and the like.

The composition of the present invention can be administered safely to mammals (e.g., human, dog, rabbit, cow, horse, monkey, cat, sheep, etc.).

While the dose of the composition of the present invention varies depending on the kind of disease, symptom, age and body weight of patients and the like, when it is administered to an adult, for example, the dose is preferably one or two drops per instillation in one eye according to the state of the disease, as an eye drop containing difluprednate in a concentration of about 0.005-0.1%, wherein the dose frequency is two to four times a day.

The present invention is described in more detail by way of Examples and Experimental Examples, which should not be construed as limiting the invention.

In the following Examples and Experimental Examples, the median size was measured by Shimadzu SALD-2000 laser diffraction apparatus for particle size distribution (dispersion medium: water, refractive index : 1.70-0.20i) upon addition of about 2 ml of the composition to be measured.

#### **Example 1**

Difluprednate	0.05 g
Castor oil	5.0 g
Polysorbate 80	4.0 g
Concentrated glycerol	2.0 g
Sodium acetate	0.01 g
Boric acid	0.1 g
Sodium edetate	0.02 g
Sorbic acid	0.1 g
Sodium hydroxide	suitable amount
Sterile purified water	amount to make the total 100 ml (pH 6.0)

Sterile purified water was heated to about 70°C and polysorbate 80, concentrated glycerol, sodium acetate, boric acid, sodium edetate and sorbic acid of the above formulation were added and dissolved. Its pH was adjusted to 6.0 with sodium hydroxide to give an aqueous phase. Separately, castor oil

was heated to about 70°C and difluprednate was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.06  $\mu$  m.

#### Example 2

Difluprednate	0.005 g
Castor oil	1.0 g
Polysorbate 80	0.5 g
Concentrated glycerol	2.2 g
Hydroxypropylmethylcellulose	0.1 g
Sodium acetate	0.05 g
Chlorobutanol	0.3 g
Hydrochloric acid	suitable amount
Sterile purified water	amount to make the total 100 ml (pH 4.0)

Sterile purified water was heated to about 70°C and polysorbate 80, concentrated glycerol, hydroxypropylmethylcellulose, sodium acetate and chlorobutanol of the above formulation were added and dissolved. Its pH was adjusted to 4.0 with hydrochloric acid to give an aqueous phase. Separately, castor oil was heated to about 70°C and difluprednate was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.12  $\mu$  m.

#### Example 3

Difluprednate	0.01 g
Miglyol	10.0 g
Polysorbate 80	5.0 g
Concentrated glycerol	2.2 g
$\epsilon$ -aminocaproic acid	0.05 g
Chlorhexidine gluconate	0.005 g
Sodium hydroxide	suitable amount

Sterile purified water	amount to make the total 100 ml (pH 5.5)
------------------------	---

Sterile purified water was heated to about 70°C and polysorbate 80, concentrated glycerol, ε -aminocaproic acid and chlorhexidine gluconate of the above formulation were added and dissolved. Its pH was adjusted to 5.5 with sodium hydroxide to give an aqueous phase. Separately, Miglyol was heated to about 70°C and difluprednate was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.21 μ m.

#### Example 4

Difluprednate	0.1 g
Castor oil	20.0 g
Polyoxyethylene hydrogenated castor oil 60	5.0 g
Concentrated glycerol	2.2 g
Sodium glutamate	0.01 g
Methyl p-hydroxybenzoate	0.02 g
Propyl p-hydroxybenzoate	0.01 g
Sodium hydroxide	suitable amount
Sterile purified water	amount to make the total 100 ml (pH 5.0)

Sterile purified water was heated to about 70°C and polyoxyethylene hydrogenated castor oil 60, concentrated glycerol, sodium glutamate, methyl p-hydroxybenzoate and propyl p-hydroxybenzoate of the above formulation were added and dissolved. Its pH was adjusted to 5.0 with sodium hydroxide to give an aqueous phase. Separately, castor oil was heated to about 70°C and difluprednate was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.06 μ m.

#### Example 5

Difluprednate	0.05 g
Castor oil	8.0 g
Polysorbate 80	5.0 g
Polyvinyl alcohol	0.02 g
Concentrated glycerol	2.2 g
Sodium acetate	0.1 g
Benzalkonium chloride	0.01 g
Hydrochloric acid	suitable amount
Sterile purified water	amount to make the total 100 ml (pH 5.0)

Sterile purified water was heated to about 70°C and polysorbate 80, polyvinyl alcohol, concentrated glycerol, sodium acetate and benzalkonium chloride of the above formulation were added and dissolved. Its pH was adjusted to 5.0 with hydrochloric acid to give an aqueous phase. Separately, castor oil was heated to about 70°C and difluprednate was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.06  $\mu$  m.

#### **Example 6**

Difluprednate	0.01 g
Miglyol	5.0 g
Polysorbate 80	4.0 g
Concentrated glycerol	2.0 g
Sodium hydrogenphosphate	0.05 g
Sodium edetate	0.01 g
Benzalkonium chloride	0.005 g
Sodium hydroxide	suitable amount
Sterile purified water	amount to make the total 100 ml (pH 7.0)

Sterile purified water was heated to about 70°C and polysorbate 80, concentrated glycerol, sodium hydrogenphosphate, sodium edetate and benzalkonium chloride of the above formulation were added and dissolved. Its pH was adjusted to 7.0 with sodium hydroxide to give an aqueous phase. Separately, Miglyol was heated to about 70°C and difluprednate was added

and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.06  $\mu$  m.

#### **Example 7**

Difluprednate	0.05 g
Castor oil	5.0 g
Polysorbate 80	4.0 g
Concentrated glycerol	2.2 g
Sodium acetate	0.05 g
Sodium edetate	0.02 g
Boric acid	0.1 g
Sorbic acid	0.1 g
Sodium hydroxide	suitable amount
Sterile purified water	amount to make the total 100 ml (pH 5.5)

Sterile purified water was heated to about 70°C and polysorbate 80, concentrated glycerol, sodium acetate, sodium edetate, boric acid and sorbic acid of the above formulation were added and dissolved. Its pH was adjusted to 5.5 with sodium hydroxide to give an aqueous phase. Separately, castor oil was heated to about 70°C and difluprednate was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.06  $\mu$  m.

#### **Example 8**

Difluprednate	0.01 g
Castor oil	5.0 g
Polysorbate 80	4.0 g
Concentrated glycerol	2.2 g
Sodium acetate	0.05 g
Sodium edetate	0.02 g
Boric acid	0.1 g
Sorbic acid	0.1 g

Sodium hydroxide	suitable amount
Sterile purified water	amount to make the total 100 ml
	(pH 5.5)

Sterile purified water was heated to about 70°C and polysorbate 80, concentrated glycerol, sodium acetate, sodium edetate, boric acid and sorbic acid of the above formulation were added and dissolved. Its pH was adjusted to 5.5 with sodium hydroxide to give an aqueous phase. Separately, castor oil was heated to about 70°C and difluprednate was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.06  $\mu$  m.

#### **Example 9**

Difluprednate	0.002 g
Castor oil	5.0 g
Polysorbate 80	4.0 g
Concentrated glycerol	2.2 g
Sodium acetate	0.05 g
Sodium edetate	0.02 g
Boric acid	0.1 g
Sorbic acid	0.1 g
Sodium hydroxide	suitable amount
Sterile purified water	amount to make the total 100 ml
	(pH 5.5)

Sterile purified water was heated to about 70°C and polysorbate 80, concentrated glycerol, sodium acetate, sodium edetate, boric acid and sorbic acid of the above formulation were added and dissolved. Its pH was adjusted to 5.5 with sodium hydroxide to give an aqueous phase. Separately, castor oil was heated to about 70°C and difluprednate was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion. This crude emulsion was finely divided in a microfluidizer and sterilized by filtration to give a composition of the present invention. The median size of the oil drop in the composition of the present invention was 0.06  $\mu$  m.

#### **Experimental Example 1**

The transfer into anterior chamber (intraocular transfer) of rabbits was compared between a difluprednate ophthalmic suspension and the composition of the present invention after a single instillation thereof.

A difluprednate ophthalmic suspension, which is a steroidal agent, has been already known to have significant inhibitory effect on rabbits with experimental uveitis. In this Experiment, transfer of difluprednate into anterior chamber (intraocular transfer) was compared between a difluprednate ophthalmic suspension and the composition of the present invention, in an attempt to improve intraocular transfer of difluprednate.

#### **(1) Test composition**

The composition of the present invention and an ophthalmic suspension having the formulations shown in Table 1 were prepared as in the following.

##### **[composition of the present invention]**

Sterile purified water (800 ml) was heated to about 70°C, and polysorbate 80 (40 g) and concentrated glycerol (26 g) were added and dissolved to give an aqueous phase. Separately, castor oil (50 g) was heated to about 70°C, and difluprednate (0.5 g) was added and dissolved to give an oil phase. The oil phase was added while stirring the aqueous phase with a homomixer to give a crude emulsion, and sterile purified water was added to make the total amount 1000 ml. This crude emulsion was finely divided in a microfluidizer. Sterilization by filtration gave the composition of the present invention.

##### **[ophthalmic suspension]**

Sterile purified water (800 ml) was heated to about 70°C and hydroxypropylmethylcellulose (2 g) was added. After thorough dispersion, the mixture was cooled to about 30°C, and hydroxypropylmethylcellulose was added. Then, sodium acetate (1 g), sodium chloride (8 g) and benzalkonium chloride solution (10 w/v%, 0.5 ml) were added and dissolved. Its pH was adjusted to 5.0 with hydrochloric acid and the mixture was sterilized by filtration. Difluprednate (1 g) was added and thoroughly suspended. Sterile purified water was added to make the total amount 1000 ml, whereby the ophthalmic suspension was obtained.



**Table 1**

(in 100 ml)

Formulation	suspension (R.P.1)	composition of the present invention (R.P.2)
Difluprednate	0.1 g	0.05 g
Sodium acetate	0.1 g	—
HPMC (60SH50)	0.2 g	—
Sodium chloride	0.8 g	—
Benzalkonium chloride	0.005 g	—
Hydrochloric acid	suitable amount	—
Sterile purified water	suitable amount	suitable amount
Castor oil	—	5.0 g
Polysorbate 80	—	4.0 g
Concentrated glycerol	—	2.6 g
pH	5.0	6.5
Median size	4.0 $\mu$ m	0.16 $\mu$ m

(HPMC: hydroxypropylmethylcellulose)

**(2) Test animal**

Male Japanese albino rabbits weighing about 2 kg and having no abnormalities in the eye were used. These rabbits were reared in a rearing chamber set to the conditions of room temperature  $23 \pm 3^\circ\text{C}$  and relative humidity  $55 \pm 10\%$ , each chamber housing one rabbit. The rabbits were fed with solid feed (100 g per day, Labo RG-RO, NIHON NOSAN KOGYO K.K.) and allowed to have a free access to tap water.

**(3) Test method**

The test composition (50  $\mu$  l) was instilled in the eye, and one hour later, the rabbits were slaughtered with pentobarbital. Immediately after slaughter, anterior ocular segment was washed with physiological saline and aqueous humor was taken. Since difluprednate is deesterified at 21 position in aqueous humor and the like and metabolized into DFB (6  $\alpha$ , 9  $\alpha$  - difluoroprednisolone 17-butyrate), DFB was measured by high performance liquid chromatography (HPLC) and taken as an index of difluprednate concentration in anterior chamber. The HPLC conditions were as follows.

HPLC conditions:

column : TSK gel ODS-80Ts

mobile phase : 10mM NaH<sub>2</sub>PO<sub>4</sub> · 2H<sub>2</sub>O(pH7)/CH<sub>3</sub>CN = 55/45

column temperature : 40°C

flow rate : 1.3 ml/min

wavelength : 240 nm

amount injected : 50 µl

The DFB concentration in the anterior chamber of the eye of rabbits after one hour from a single instillation of the test composition is shown in Table 2.

**Table 2**  
DFB concentration in aqueous humor

	test composition	
	suspension (R.P.1)	composition of the present invention (R.P.2)
DFB concentration (ng/ml)	19.15±2.8	42.95±6.5

Each value shows mean±S.E. (N=7-8).

When difluprednate was prepared into a composition of the present invention, the amount of intraocular transfer was 42.95 ng/ml, despite the fact that the drug concentration in the composition was half the amount thereof in the suspension. This value was about 2.2 times greater than that in the case of the suspension, and significant difference was found. The above results reveal that the composition of the present invention shows efficacy greater than that afforded by a suspension even in a smaller dose.

Thus, the composition of the present invention has superior antiinflammatory action and antiallergic action.

In addition, the composition of the present invention shows superior transfer to a lesion as well as uniform drug distribution upon administration, as compared to conventional preparations containing difluprednate, so that it

shows sufficient efficacy in a smaller dose. The inventive composition is associated with extremely less uncomfortable feeling and foreign sensation upon administration, as compared to conventional preparations containing difluprednate, and it can be administered easily to local sites of eye, nose, ear and the like.

This application is based on application No. 21807/1997 filed in Japan, the content of which is incorporated hereinto by reference.

#### **WHAT IS CLAIMED IS**

1. A difluprednate liquid composition comprising difluprednate, oil, water and an emulsifier.
2. The composition of claim 1, comprising 10-100,000 parts by weight of oil, 100-100,000 parts by weight of water and 10-100,000 parts by weight of the emulsifier, per part by weight of difluprednate.
3. The composition of claim 1, comprising 10-10,000 parts by weight of oil, 100-50,000 parts by weight of water and 10-10,000 parts by weight of the emulsifier, per part by weight of difluprednate.
4. The composition of claim 1, comprising 10-5,000 parts by weight of oil, 500-50,000 parts by weight of water and 10-5,000 parts by weight of the emulsifier, per part by weight of difluprednate.
5. The composition of claim 1, wherein the oil comprises a fatty acid ester of glycerol.
6. The composition of claim 5, wherein the fatty acid ester of glycerol is a member selected from the group consisting of castor oil, peanut oil, cotton seed oil, soybean oil, olive oil and a medium chain fatty acid triglyceride.
7. The composition of claim 1, wherein the emulsifier comprises a surfactant.
8. The composition of claim 7, wherein the surfactant is a nonionic surfactant.
9. The composition of claim 8, wherein the nonionic surfactant is a member selected from the group consisting of polyoxyethylene hydrogenated castor oil and a polyoxyethylenesorbitan fatty acid ester.
10. The composition of claim 9, wherein the polyoxyethylenesorbitan fatty acid ester is a member selected from the group consisting of polyoxyethylenesorbitan monooleate, polyoxyethylenesorbitan monolaurate, polyoxyethylenesorbitan monopalmitate and polyoxyethylenesorbitan monostearate.

11. The composition of any one of claims 1 to 4, which is an oil-in-water type emulsion.

12. The composition of any one of claims 1 to 4, which is in the form of an eye drop, a nasal drop or an ear drop.

### **ABSTRACT OF THE DISCLOSURE**

The present invention relates to a liquid composition comprising difluprednate, oil, water and an emulsifier. The composition of the present invention has superior antiinflammatory action and antiallergic action. The composition of the present invention shows superior transfer to a lesion and uniform drug distribution upon administration, as compared to conventional preparations containing difluprednate, so that it shows sufficient efficacy in a smaller dose. The inventive composition is associated with extremely less uncomfortable feeling and foreign sensation upon administration, as compared to conventional preparations containing difluprednate, and it can be administered easily to local sites of eye, nose, ear and the like.

# DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original      ( ) Supplemental      ( ) Substitute      ( ) PCT      ( ) Design

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: COMPOSITIONS CONTAINING DIFLUPREDNATE

of which is described and claimed in:

(X) the attached specification, or

( ) the specification in the application Serial No. \_\_\_\_\_ filed \_\_\_\_\_;  
and with amendments through \_\_\_\_\_ (if applicable), or

( ) the specification in International Application No. PCT/ \_\_\_\_\_, filed \_\_\_\_\_, and as amended  
on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	124415/1997	May 14, 1997	X

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint John T. Miller, Reg. No. 21,120; Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Jeffrey Nolton, Reg. No. 25,408; Warren M. Cheek, Jr., Reg. No. 33,367; Nils E. Pedersen, Reg. No. 33,145 and Charles R. Watts, Reg. No. 33,142, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys named herein to accept and follow instructions from TAKASHIMA INTERNATIONAL PATENT OFFICE as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Send Correspondence to

WENDEROTH, LIND & PONACK, L.L.P.  
2033 K Street, N.W., Suite 800  
Washington, DC 20006

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P.  
Area Code (202) 721-8200

Direct Facsimile Messages to:

Area Code (202) 721-8250

<b>Full Name of First Inventor</b>	<b>FAMILY NAME</b> Kimura	<b>FIRST GIVEN NAME</b> Masako	<b>SECOND GIVEN NAME</b>
<b>Residence &amp; Citizenship</b>	<b>CITY</b> Kakogawa-shi, Hyogo,	<b>STATE OR COUNTRY</b> Japan	<b>COUNTRY OF CITIZENSHIP</b> Japan
<b>Post Office Address</b>	<b>ADDRESS</b> 527-3, Kitano. Noguchi-cho. Kakogawa-shi, Hyogo	<b>CITY</b> Japan	<b>STATE OR COUNTRY</b> ZIP CODE 675-0011 Japan
<b>Full Name of Second Inventor</b>	<b>FAMILY NAME</b> Yasueda	<b>FIRST GIVEN NAME</b> Shin-ichi	<b>SECOND GIVEN NAME</b>
<b>Residence &amp; Citizenship</b>	<b>CITY</b> Kobe-shi, Hyogo,	<b>STATE OR COUNTRY</b> Japan	<b>COUNTRY OF CITIZENSHIP</b> Japan
<b>Post Office Address</b>	<b>ADDRESS</b> 5-502. Babadouri 1-chome. Tarumi-ku. Kobe-shi, Hyogo	<b>CITY</b> Japan	<b>STATE OR COUNTRY</b> ZIP CODE 655-0021 Japan
<b>Full Name of Third Inventor</b>	<b>FAMILY NAME</b> Yamaguchi	<b>FIRST GIVEN NAME</b> Masazumi	<b>SECOND GIVEN NAME</b>
<b>Residence &amp; Citizenship</b>	<b>CITY</b> Kobe-shi, Hyogo,	<b>STATE OR COUNTRY</b> Japan	<b>COUNTRY OF CITIZENSHIP</b> Japan
<b>Post Office Address</b>	<b>ADDRESS</b> 366-1-101, Minamibefu 4-chome. Nishi-ku. Kobe-shi, Hyogo	<b>CITY</b> Japan	<b>STATE OR COUNTRY</b> ZIP CODE 651-2116 Japan
<b>Full Name of Fourth Inventor</b>	<b>FAMILY NAME</b> Inada	<b>FIRST GIVEN NAME</b> Katsuhiro	<b>SECOND GIVEN NAME</b>
<b>Residence &amp; Citizenship</b>	<b>CITY</b> Kobe-shi, Hyogo,	<b>STATE OR COUNTRY</b> Japan	<b>COUNTRY OF CITIZENSHIP</b> Japan
<b>Post Office Address</b>	<b>ADDRESS</b> 2-1-3-401, Ibukidaihigashimachi 1-chome. Nishi-ku. Kobe-shi, Hyogo	<b>CITY</b> Japan	<b>STATE OR COUNTRY</b> ZIP CODE 651-2242 Japan



Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Seventh Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Masako Kimura (Masako Kimura) Date April 28, 1998  
 2nd Inventor Shinichi Yasueda (Shin-ichi Yasueda) Date April 28, 1998  
 3rd Inventor Masazumi Yamaguchi (Masazumi Yamaguchi) Date April 28, 1998  
 4th Inventor Katsuhiro Inada (Katsuhiro Inada) Date April 28, 1998  
 5th Inventor \_\_\_\_\_ Date \_\_\_\_\_  
 6th Inventor \_\_\_\_\_ Date \_\_\_\_\_  
 7th Inventor \_\_\_\_\_ Date \_\_\_\_\_

The above application may be more particularly identified as follows:


U.S. Application Serial No. \_\_\_\_\_ Filing Date \_\_\_\_\_

Applicant Reference Number \_\_\_\_\_ Atty Docket No. \_\_\_\_\_

Title of Invention \_\_\_\_\_

# United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



## Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:

- ☐ All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11". Pages \_\_\_\_\_ do not meet these requirements.
- ☐ Papers are not flexible, strong, smooth, non-shiny, durable, and white.
- ☐ Papers are not typewritten or mechanically printed in permanent ink on one side.
- ☐ Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
- ☐ Papers contain hand lettering.

2. Drawings are not in compliance and were not scanned because:

- ☐ The drawings or copy of drawings are not suitable for electronic reproduction.
- ☐ All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
- ☐ Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").

3. Page(s) \_\_\_\_\_ are not of sufficient clarity, contrast and quality for electronic reproduction.

4. Page(s) \_\_\_\_\_ are missing.

5. OTHER: No Drawings